Citatuzumab

Citatuzumab is a monoclonal antibody designed for the treatment of cancer. This drug was developed by Immunomedics Inc.

History

Citatuzumab was one of the many drugs developed by Immunomedics Inc., a company that specializes in the development of monoclonal antibody-based products for the targeted treatment of cancer. The drug was designed to target and destroy cancer cells while sparing healthy cells, a common goal in cancer treatment.

Mechanism of Action

As a monoclonal antibody, Citatuzumab works by binding to specific proteins on the surface of cancer cells. This binding triggers the immune system to attack and destroy the cancer cells. The specific target of Citatuzumab is not publicly disclosed.

Clinical Trials

Citatuzumab has undergone various clinical trials to test its safety and efficacy in treating cancer. The results of these trials are not publicly available.

See Also

• Monoclonal antibodies
• Immunomedics
• Cancer treatment

References

Citatuzumab Resources
Need Help Finding a Doctor? Need help finding a doctor or specialist anywhere in the world? Explore our world directory. WikiMD's DocFinder can assist you in locating millions of physicians.	Medical Knowledge Access the latest research - Most recent articles Ongoing trials.

Translate to: East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski